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Purpose: Buprenorphine transdermal system is increasingly prescribed in people with advanced 
dementia, but no clinical trial has investigated the safety and factors associated with discontinu-
ation due to adverse events in this population.
Patients and methods: One hundred sixty-two people with advanced dementia and significant 
depression from 47 nursing homes were included and randomized to active analgesic treatment 
(acetaminophen/buprenorphine) or identical placebo for 13 weeks. In this secondary analysis, 
the main outcomes were time to and reasons for discontinuation of buprenorphine due to adverse 
events. Change in daytime activity as measured by actigraphy was a secondary outcome.
Results: Of the 44 patients who received active buprenorphine 5 µg/hour, 52.3% (n=23) dis-
continued treatment due to adverse events compared to 13.3% (6 of 45) in the placebo group 
(p,0.001). Psychiatric and neurological adverse events were the most frequently reported 
causes of discontinuation (69.6%, n=16). Concomitant use of antidepressants significantly 
increased the risk of discontinuation (HR 23.2, 95% CI: 2.95–182, p=0.003). Adjusted for age, 
sex, cognitive function, pain and depression at baseline, active buprenorphine was associated 
with 24.0 times increased risk of discontinuation (Cox model, 95% CI: 2.45–235, p=0.006). 
Daytime activity dropped significantly during the second day of active treatment (−21.4%, 
p=0.005) and decreased by 12.9% during the first week (p=0.053).
Conclusion: Active buprenorphine had significantly higher risk of discontinuation compared 
with placebo in people with advanced dementia and depression, mainly due to psychiatric and 
neurological adverse events. Daytime activity dropped significantly during the first week of treat-
ment. Concomitant use of antidepressants further reduced the tolerability of buprenorphine.
Keywords: opioids, analgesics, dementia, drug safety, adverse drug reactions
Introduction
More than 80% of elderly people in long-term residential care have dementia.1 
Approximately 50% of these individuals suffer from pain of clinically significant 
intensity.2 Cognitive impairment leads to difficulty in verbally expressing painful 
symptoms and complicates the assessment and treatment of pain.3 This may increase 
the risk of untreated chronic pain in people with dementia compared with cognitively 
intact patients.4 In the past few decades, systematic reviews have expressed concern 
that nursing home patients with dementia receive less analgesic treatment than those 
without dementia, despite comparable diagnoses of pain.5,6
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Data from the entire population of Denmark in 2010 
showed that 41% of the country’s 42,291 nursing home 
patients used opioids, and that patients without dementia 
received significantly more opioid analgesics compared with 
those with dementia (43% and 38%, respectively).7 A study 
including 425 patients from 12 nursing homes in Austria 
in 2011–2012 found that despite having more pain, fewer 
cognitively impaired patients received scheduled analgesic 
prescriptions compared with patients without cognitive 
impairment (36% and 58%, respectively).8 Several studies 
have reported similar rates of analgesic use in nursing home 
patients with and without dementia,9,10 with an overall 
increase in total analgesic use irrespective of cognitive 
state and a shift toward increased use of opioid analgesics.9 
In Norway, the use of opioid analgesics in nursing home 
patients increased from 11% in 2000 to 24% in 2011, with a 
substantial increase in the use of strong opioids from 1.9% 
to 17.9%.9 In 2011, the odds ratio for the use of strong opioids 
in nursing home patients with dementia did not differ signifi-
cantly compared with those without dementia.9
Buprenorphine transdermal system (TDS) has been 
recommended for elderly patients because of its favorable 
pharmacodynamic and pharmacokinetic profile, with low 
risk of serious adverse events.11 Buprenorphine, a strong 
opioid, is a partial mu receptor agonist and a kappa receptor 
antagonist. This pattern of activity gives a ceiling effect for 
respiratory depression, without a clinically relevant ceiling 
effect on analgesia.12 As one of few opioids, it does not 
require dose adjustment in renal insufficiency due to hepatic 
clearance.13 Buprenorphine TDS is prescribed to over 10% 
of nursing home patients in countries where it is marketed, 
with estimated use in people with dementia ranging from 
10.5% to 14.8%.7,9,10 While buprenorphine TDS has shown 
high persistence rates in the general population, the rate of 
common adverse events such as nausea, dizziness, or sedation 
is higher than that of comparator opioids.14,15 Dementia, age-
related physiological changes, multimorbidity, frailty, and 
interactions with psychotropic drugs may impact the safety 
and tolerability of buprenorphine TDS.16
There is a well-documented association between pain and 
increased depressive symptoms in people with dementia,17 
and antidepressants have questionable efficacy for depression 
in these patients.18 In a recent study, we investigated whether 
analgesic treatment with acetaminophen or buprenorphine 
TDS could improve depression in people with dementia. 
Contrary to our hypothesis, we found that active treatment 
was associated with more persistent depressive symptoms, 
and 52% of patients who received active buprenorphine 
were withdrawn from the study due to adverse events dur-
ing treatment.39 Few studies have assessed the tolerability 
and adverse effects of buprenorphine TDS in nursing home 
patients with dementia, and none with a placebo-controlled 
design. Furthermore, buprenorphine may have additive or 
synergistic interaction effects with other drugs that have seda-
tive effects. Elderly patients and people with dementia are 
particularly vulnerable to adverse effects such as sedation, but 
interactions between opioids and other commonly prescribed 
psychotropic drugs such as antidepressants have not been 
studied in this population. Similarly, anticholinergic drugs 
may negatively impact cognition in people with dementia, but 
we do not know whether high anticholinergic drug burden is 
associated with poorer tolerability of buprenorphine. There 
is a need to investigate clinically significant interactions 
between opioids and anticholinergic and psychotropic drugs 
in people with dementia.
In these secondary analyses of our study, the primary 
aim was to assess the tolerability of buprenorphine TDS in 
nursing home patients with moderate to severe dementia, 
controlling for pain intensity, depressive symptoms, cogni-
tive state, and concomitant use of psychotropic and anti-
cholinergic drugs. Secondary aims were to assess which 
adverse effects most frequently caused discontinuation and 
to determine how daytime activity changed during the first 
week of treatment.
Patients and methods
study design and population
The current study comprises secondary analyses of data 
collected in the randomized, placebo-controlled trial 
“Efficacy of analgesic treatment for depression in nursing 
home patients with dementia (DEP.PAIN.DEM),” which 
was conducted in 47 nursing homes in 10 municipalities of 
Norway, including people with dementia (Mini-Mental State 
Examination [MMSE] #20) and depression (Cornell Scale 
for Depression in Dementia [CSDD] $8; full inclusion and 
exclusion criteria are presented in Table 1). The intervention 
consisted of a stepwise increase in analgesic treatment, and 
patients who did not use scheduled analgesics at baseline or 
used acetaminophen #1 g/day were prescribed acetamino-
phen in a total dose of 1 g three times daily. Patients who 
already used acetaminophen .1 g daily, nonsteroidal antiin-
flammatory drugs (except low-dose acetylsalicylic acid), or 
buprenorphine 5 µg/hour, or who had difficulty swallowing 
tablets, were prescribed buprenorphine TDS 5 µg/hour in 
addition to their regular treatment and randomized to receive 
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adjustment.39 Patients who received buprenorphine/placebo 
TDS are included in the current analyses.
Procedures
Clinicians were advised to keep doses of psychotropic 
and analgesic drugs unchanged during the study period, if 
possible. If lasting changes were made to regular analgesic 
treatment or antidepressants, the patient was withdrawn 
from the study. The study treatment was prescribed in 
addition to any regular or as-needed analgesics. In mild to 
moderate acute pain, patients were given as-needed analge-
sics in addition to study treatment, and the number of doses 
given during the study period was recorded. Patients with 
severe pain at baseline were excluded because it would be 
unethical to risk treating them with a placebo. We there-
fore ensured that the included patients would not suffer 
from prolonged or unnecessary untreated pain because of 
the study protocol. Furthermore, the physician who was 
responsible for the patient had full authority to discontinue 
study treatment promptly if clinical changes necessitated 
treatment with a known dose of active analgesic. Written 
informed consent was obtained from patients with medical 
decision-making capacity, or written presumed consent 
was obtained from a legally authorized representative in 
those with reduced capacity to consent in accordance with 
ethics committee requirements and current Norwegian 
legislation. The trial was approved by the Regional Com-
mittee for Medical and Health Research Ethics (REC-
West 2013/1474) and the Norwegian Medicines Agency 
(EudraCT 2013-002226-23), and registered at ClinicalTri-
als.gov (NCT02267057).
randomization and masking
The trial was double blinded, and participants were ran-
domly allocated to each arm in a 1:1 ratio according to 
computer-generated random numbers in blocks of 12 with 
no stratification factors. Buprenorphine TDS and identical, 
inert placebo (Mundipharma Research Limited, Cambridge, 
UK) were packed and marked indiscernibly, identifiable only 
by pack number. Patients, nursing home staff, physicians, 
pharmacy, researchers, and statisticians were all masked to 
group identity until completion of the analyses.
Assessments
Assessments were made by the researchers in collabora-
tion with the nursing home staff and included scheduled 
assessments at baseline, 6 and 13 weeks in addition to any 
spontaneous reports during the whole 13-week period. The 
tolerability of buprenorphine TDS was operationalized by 
assessing how many patients discontinued treatment due to 
adverse events (defined as suspected adverse event, clinical 
deterioration, or death) and how long treatment lasted before 
such discontinuation. Discontinuation for other reasons, such 
as protocol violation, was not included in the analysis, and 
in the following, “discontinuation” refers only to those cases 
defined here as caused by adverse events. To ensure that 
all suspected adverse events were reported, the proxy rater 
received standardized detailed verbal and written information 
Table 1 Inclusion and exclusion criteria
Type of criterion Patient characteristics
Inclusion criteria Age $60 years
long-term nursing home placement with .4 weeks’ stay
Dementia (MMse #20)
Depression (CsDD $8, .3 weeks’ duration)
exclusion criteria life expectancy ,6 months
severe medical disease that could interfere with study participation
Impaired liver function, assessed by elevated serum alanine aminotransferase
severe renal impairment with serum creatinine indicative of egFr #30 (Cockcroft–gault equation)
Anemia (hb ,8.5 mmol/l for men, ,7.5 mmol/l for women) or electrolyte imbalance (na+, K+)
history of severe psychiatric disease prior to dementia onset
suicide risk (any attempts during the last year)
severe aggression (nPI-nh aggression item score $8, with aggression as the predominant symptom)
severe pain (MOBID-2 $8)
Uncontrolled epilepsy
Contraindication or clinically significant drug interaction to the assigned study treatment
regular use of any opioid analgesic other than or exceeding buprenorphine 5 µg/hour
Cognitive impairment related to diagnoses other than Alzheimer’s disease, frontotemporal dementia, 
vascular dementia, dementia with lewy bodies, or mixed dementia
Abbreviations: CSDD, Cornell Scale for Depression in Dementia; eGFR, estimated glomerular filtration rate; MMSE, Mini-Mental State Examination; MOBID-2, Mobilization-
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about known possible adverse effects of buprenorphine. They 
were instructed to pay attention to and report changes in any 
of the symptoms listed as potential adverse events, as well 
as any other clinical changes that occurred during treatment. 
If any clinical changes were observed during treatment, the 
raters were instructed to contact the researchers by phone 
immediately to report the symptoms. This information was 
distributed to other staff members, along with instructions 
to contact the researchers by phone immediately upon 
suspicion of any adverse event. In addition, the research-
ers asked specifically whether any adverse events were 
suspected at other contacts with the nursing home staff and 
during scheduled follow-up at 6 and 13 weeks of treatment. 
All suspected adverse events, irrespective of whether the 
patient discontinued treatment, were recorded verbatim as 
reported by nursing home staff, in as much detail as possible, 
including information about time from initiation to presenting 
symptoms and discontinuation of treatment.
Demographic information and a complete list of sched-
uled drug prescriptions (excluding prescriptions given pro re 
nata, ie, “as needed”) were extracted from the patients’ 
medical records at baseline. The total number of scheduled 
drug prescriptions was counted. Analgesic use was assessed 
by counting the number of prescriptions for drugs classified as 
systemic analgesics (Anatomical Therapeutic Chemical 
[ATC] code N02 or M01A). In addition, the individual 
and total numbers of scheduled psychotropic drugs were 
counted (antidepressants [N06A], anti-dementia [N06D], 
antipsychotic [N05A], anxiolytic [N05B], hypnotic and 
sedative [N05C], and antiepileptic [N03A] drugs). The total 
anticholinergic cognitive burden (ACB) was calculated by 
assigning 1 point for each prescribed drug with mild anti-
cholinergic properties, 2 points for each drug with moderate 
anticholinergic effects, and 3 points for each drug with strong 
anticholinergic properties.19,20 Between-group differences 
in drug use and morbidity at baseline were assessed by 
counting the number of prescriptions for drugs within each 
ATC group (A–V).
Activity was assessed by actigraphy registration using 
the Philips Actiwatch Spectrum, which was worn on the 
patients’ dominant or mobile wrist continuously for 14 days 
(7 days before and 7 days after treatment was started).21,22 
Total activity counts per day (Total AC) and mean intensity 
of activity per minute (AC/minute) for daily 12-hour intervals 
(09:00–21:00) were extracted from the Respironics Actiware 
6.0.9 software. Mean activity counts for Total AC and 
AC/minute were calculated for both 7-day periods in all patients 
with at least 5 valid days of actigraphy recording per week.
Cognitive function was assessed using the MMSE, a 
30-item questionnaire administered directly to the patient cov-
ering 11 domains (registration, orientation to time and place, 
short-term recall, attention, calculation, long-term recall, 
naming, repetition, comprehension [verbal and written], 
writing, and visuospatial construction) to yield a sum score 
from 0 (most severe impairment) to 30 (no impairment).23,24
Pain was assessed using the Mobilization-Observation-
Behavior-Intensity-Dementia-2 Pain Scale (MOBID-2), 
a two-part staff-administered instrument to assess pain in 
people with advanced dementia.25 The proxy evaluation of 
inferred pain intensity is based on the patient’s pain behaviors 
during standardized, guided movements of different body 
parts (Part 1), and pain behaviors that might be related to 
internal organs, head, and skin are recorded on an anatomical 
figure along with the inferred pain intensity for each region to 
allow monitoring over time (Part 2). The scale yields a final 
score from 0 (no pain) to 10 (worst pain imaginable). Good 
interrater and test–retest reliability, internal consistency, and 
validity have been shown, and the MOBID-2 scale has also 
demonstrated responsiveness to change.25
Depressive symptoms were assessed using the CSDD, 
which is a validated and widely used screening tool for depres-
sion in people with dementia.26 It is administered by an inter-
view with a proxy rater who is familiar with the patient, and 
it contains 19 items in five domains (mood-related signs, 
behavioral disturbance, physical signs, cyclic functions, and 
ideational disturbance). Each item is rated from 0 (no symp-
tom) to 2 (severe symptoms) to yield a sum score of between 
0 (no depression) and 38 (most severe depression).26
The main outcome measure was time to discontinuation 
of treatment due to adverse events. Secondary outcome 
measures were reasons for discontinuation, and change in 
total daytime activity and mean intensity of daily activity as 
measured by actigraphy recording.
sample size calculation
The DEP.PAIN.DEM trial was designed to obtain 90% power 
to detect a 2-point CSDD difference between active treatment 
(acetaminophen or buprenorphine) and identical placebo, 
with an SD of 5, a standardized effect size of 0.4, p,0.05. 
The sample size was calculated using a sample size formula 
for longitudinal continuous response, adjusted for within-
subject correlation between repeated measurements which 
was estimated to be 0.25 using data from the first 113 patients. 
One hundred thirty-two participants (66 in each group) were 
required, and adjusting for 20% dropouts, our final aim was 
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Baseline characteristics were described as mean and standard 
deviation for continuous variables, and with the number of 
patients and percentages of the sample size for categorical 
variables. Between-group differences were tested using 
independent-samples t-test for continuous variables with 
normal distribution; Mann-Whitney U-test for continuous 
variables with non-normal distribution; and Pearson’s χ2 test 
for categorical variables. We used a Kaplan–Meier survival 
plot and Cox regression models to determine whether patients 
who were randomized to receive active buprenorphine had a 
higher risk of discontinuation compared to those who received 
placebo. Cox regression analyses were repeated with age, sex, 
and MOBID-2, CSDD, and MMSE as covariates to determine 
which variables should be included in the adjusted analyses. 
To further assess whether the risk of discontinuation of active 
buprenorphine was modified by drug use, we tested the interac-
tion between the treatment effect and each of the drug variables 
(total number of prescribed drugs, ACB score, total number of 
psychotropic drugs, and use of each class of psychotropic drugs 
[N06A, N06D, N05A, N05B, N05C, N03A]) on discontinua-
tion, both unadjusted and adjusted for age, sex, and MOBID-2, 
CSDD, and/or MMSE at baseline if these covariates impacted 
discontinuation risk. We used cluster-robust variance estimates 
to account for dependence within nursing homes. To assess 
immediate changes in daytime activity during the early days 
of treatment, we used linear mixed-effects models for Total 
AC and AC/minute/day using the mean recording from the 
7 days before treatment was initiated as baseline. Time was 
included as a categorical variable, with fixed effects for time, 
intervention, and their interaction in the models. The models 
were fitted with random intercepts for patients to account for 
correlation between longitudinal measurements, random slope 
for time, and residual error structure specified as independent 
by day. We regarded p,0.05 as significant. All statistical 
analyses were conducted with STATA/IC 15 (Stata Corp LP, 
College Station, TX, USA).
Results
In total, 162 patients were included in the DEP.PAIN.DEM 
trial: 73 were prescribed acetaminophen/placebo tablets, and 
89 patients were prescribed buprenorphine/placebo TDS and 
included in the current study. In the latter group, 44 were 
allocated to active treatment (hereafter, “active group”), and 
45 to placebo (hereafter, “placebo group”; see Figure 1). 
Characteristics of the included patients at baseline are shown in 
Table 2. The groups were comparable at baseline on all tested 
variables except that the active group received more drugs 
in ATC group M (seven patients in active treatment and one 
patient in placebo; p=0.025), and the placebo group received 
more drugs in ATC group N (mean number of prescriptions 
2.2 [SD 1.6] in the active group and 3.2 [SD 1.7] in the placebo 
group; p=0.001). From the latter ATC group, use of antidepres-
sants and total number of psychotropic drugs were significantly 
higher in the placebo group; we also found significantly higher 
ACB in the placebo group (Table 2). Fifteen patients used 
buprenorphine TDS 5 µg/hour prior to inclusion, eight of 
whom were allocated to receive active treatment.
Frequency and types of adverse events
All adverse events recorded are presented in Table 3. Because 
each patient may have had more than one adverse event of 
each type, the number of adverse events may not correspond 
to the number of patients affected unless specified. Psychiatric 
adverse events were reported most frequently, with 17 sepa-
rate adverse effects recorded in the active treatment group 
and none in the placebo group (p=0.003). Of psychiatric 
symptoms, personality changes (ie, changed emotional labil-
ity or other behavioral changes described as such) were the 
most frequent, reported in eight patients (18.2%), followed 
by confusion reported in five patients (11.4%). Neurological 
adverse events were the second most commonly reported, 
with 11 adverse effects recorded in the active treatment group 
and 2 in the placebo group (p=0.039). The most frequent neu-
rological adverse event and the single most frequent adverse 
symptom was sedation/somnolence, which was reported in 
nine patients (20.5%) receiving active treatment and two 
patients receiving placebo (4.4%, p=0.022).
rates and causes of discontinuation
Buprenorphine TDS active treatment was discontinued in 
23 patients (52.3%) due to adverse events, compared with 
6 patients (13.3%) in the placebo group (p,0.001). Mean 
time to discontinuation was 61 days (SD 36) in the active 
treatment group and 82 days (SD 24) in the placebo group. 
Within the first 14 days, nine patients (20.5%) discontinued 
active treatment, and two patients (4.4%) discontinued 
placebo. Nearly half of patients who did not tolerate active 
treatment reported several types of adverse events (Table 4). 
Psychiatric adverse events were the most frequent cause of 
discontinuation reported in 12 of 23 patients (52%). Neuro-
logical adverse events were the second most frequent cause 
of discontinuation reported in nine patients (39%), five of 
whom also had psychiatric symptoms.
Kaplan–Meier estimates of time to discontinuation are 
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to receive active buprenorphine
45 randomly allocated

























2,015 did not meet primary eligibility criteria
562 used opioid analgesics
895 did not have depression (CSDD <8)
139 did not have dementia (MMSE >20)
14 had changes in analgesic or antidepressant treatment
56 had life expectancy <6 months
14 had contraindication or allergy to study treatment
65 had psychiatric disorder which warranted exclusion
99 had blood test indicative of renal/hepatic failure and/or electrolyte imbalance/anemia
54 died prior to enrolment
87 had short-term placement or moved
30 aged <60 years
137 did not consent
9 were excluded for other reasons/reasons not recorded
Figure 1 Trial profile.
Abbreviations: CsDD, Cornell scale for Depression in Dementia; MMse, Mini-Mental state examination; nh, nursing home; TDs, transdermal system.








Agea 85.8 (7.2) 85.6 (8.5) 86.0 (5.9) 0.782
sex (female)b 67 (75.3%) 33 (75.0%) 34 (75.6%) 0.952
MMsea 7.0 (6.1) 6.8 (5.6) 7.3 (6.5) 0.737
MOBID-2a 3.1 (1.9) 2.7 (1.8) 3.5 (2.0) 0.095
CsDDa 10.9 (3.4) 10.3 (2.4) 11.5 (4.1) 0.099
Analgesicsb (n02/M01A) 78 (87.6%) 37 (84.1%) 41 (91.1%) 0.314
Antidepressantsb (n06A) 41 (46.1%) 14 (31.8%) 27 (60.0%) 0.008
Antipsychoticsb (n05A) 20 (22.5%) 8 (18.2%) 12 (26.7%) 0.338
Anti-dementia drugsb (n06D) 17 (19.1%) 5 (11.4%) 12 (26.7%) 0.066
Anxiolyticsb (n05B) 24 (27.0%) 9 (20.5%) 15 (33.3%) 0.171
Antiepilepticsb (n03A) 9 (10.1%) 5 (11.4%) 4 (8.9%) 0.699
sedatives/hypnoticsb (n05C) 26 (29.2%) 9 (20.5%) 17 (37.8%) 0.072
Total number of psychotropicsc 1.6 (1.3) 1.2 (1.1) 1.9 (1.3) 0.007
Anticholinergic drugsc (ACB) 1.4 (1.5) 0.9 (1.3) 1.8 (2.8) 0.014
Total number of drugsa 6.7 (3.0) 6.4 (3.5) 7.1 (2.5) 0.262
Notes: numbers represent mean (sD) or number of patients (%). aIndependent samples t-test. bPearson’s χ2-test. cMann–Whitney U-test.
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Patients with reported 
adverse reactionsb
25 (56.8%) 8 (17.8%) ,0.001
Patients who 
discontinued treatment
23 (52.3%) 6 (13.3%) ,0.001
neurological 11 2 0.039
sedation/somnolence 9 (20.5%) 2 (4.4%) 0.022
seizure 1 (2.3%) – 0.309
loss of coordination 1 (2.3%) – 0.309
Psychiatric 17 – 0.003
Personality changes 8 (18.2%) – 0.003
Anxiety 1 (2.3%) – 0.309
Agitation 2 (4.5%) – 0.148
Confusion 5 (11.4%) – 0.020
hallucinations 1 (2.3%) – 0.309
gastrointestinal 6 – 0.117
Dry mouth 1 (2.3%) – 0.309
nausea 3 (6.8%) – 0.075
Vomiting 1 (2.3%) – 0.309
Anorexia 1 (2.3%) – 0.309
Dermatological
Application site rash – 1 (2.2%) 0.320
Other 8 2 0.204
Fall 4 (9.1%) 1 (2.2%) 0.159
Fracture 1 (2.3%) 1 (2.2%) 0.987
respiratory tract 
infection
1 (2.3%) – 0.309
hospitalization 2 (4.5%) – 0.148
Deterioration/death 6 (13.6%) 4 (8.9%) 0.478
Notes: Bold figures indicate significantly different prevalence rates (p,0.05). 
aPearson’s χ2-test. beach patient may have had more than one reaction.
Table 4 symptom combinations reported in the 23 patients who discontinued active buprenorphine due to adverse events
























received active treatment had 4.7 times higher risk of dis-
continuation compared with those who received placebo 
(Table 5; Cox proportional hazards model, unadjusted 
HR, 95% CI: 1.66–13.3, p=0.004). Adjusted for age, sex, 
MOBID-2, CSDD, and MMSE at baseline, active treatment 
was associated with 24.0 times higher risk of discontinuation 
(95% CI: 2.45–235, p=0.006). In this model, age, sex, depres-
sive symptoms, and pain were not significantly associated 
with discontinuation (age: HR 1.0, 95% CI: 0.99–1.11, 
p=0.133; sex: HR 0.32, 95% CI: 0.10–1.58, p=0.149; CSDD: 
HR 1.1, 95% CI: 0.90–1.34, p=0.343; MOBID-2: HR 1.1, 
95% CI: 0.91–1.45, p=0.246). Lower MMSE scores were 
associated with increased risk of discontinuation (HR 0.82, 
95% CI: 0.71–0.94, p=0.005), but interaction effects of 
MMSE score were tested in a new model and were not signifi-
cant, that is, patients who received active treatment were not 
at increased risk of discontinuation if they had lower MMSE 
scores (HR 1.04, 95% CI: 0.82–1.31, p=0.767).
Drug use and rates of discontinuation
Total number of prescribed drugs, ACB score, total 
number of psychotropic drugs, and use of any individual 
psychotropic drug (N06A, N06D, N05A, N05B, N05C, or 
N03A; dichotomized) were all not independently associ-
ated with discontinuation of the study treatment (active or 
placebo). However, patients who received active treatment 
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discontinuation compared with patients who used antidepres-
sants and received placebo (95% CI: 2.75–170, p=0.003; 
Table 5). The interaction between active buprenorphine 
and antidepressant use remained unchanged when adjusting 
for age, sex, and MMSE (HR 23.2, 95% CI: 2.95–182, 
p=0.003). In this model, active buprenorphine was not sig-
nificantly associated with increased risk of discontinuation in 
patients who did not use antidepressants (HR 2.95, 95% CI: 
0.53–16.6, p=0.218), as shown in Figure 3 (Table 5). Interac-
tion effects were calculated separately for each variable for 
drug use, and none except antidepressant use had significant 
interactions with active buprenorphine.
Although patients who used antidepressants and received 
active treatment had significantly increased risk of discon-
tinuation, we were not able to detect any significant differ-
ence in the total number of adverse events and treatment 
discontinuations compared with those who did not use anti-
depressants. Nine of the 14 patients (64.3%) who received 
active treatment and used antidepressants reported adverse 
events and discontinued treatment. Of the 30 patients who 
received active treatment and did not use antidepressants, 16 
(53.3%) reported adverse events and 14 (46.7%) discontinued 
treatment. Using χ2-tests, the rates of adverse events and 
discontinuation in patients who received active treatment and 
used antidepressants were compared to those who did not 
use antidepressants (groups defined by the number of pre-
scriptions for antidepressants at baseline), but no significant 
differences were found (p=0.599 and 0.419, respectively). 
We did not find that patients who used antidepressants 
reported any single type of adverse event more frequently, 
except confusion which was reported in three patients who 
used antidepressants (21.4%) and two patients who did not 
use antidepressants (6.7%, p=0.013, χ2-test).
Changes in activity during the first week 
of treatment
Day-to-day activity counts in the first week of treatment, 
measured by actigraphy, are shown in Figure 4 with the 
Figure 2 Kaplan–Meier survival plot: duration of study treatment.
Table 5 estimated treatment effect of buprenorphine versus 
placebo on discontinuation (Cox regression)
N HR (95% CI) p-value
Unadjusted 89 4.70 (1.66–13.3) 0.004
Model 1a 76 7.19 (1.65–31.3) 0.009
Model 2b 65 24.0 (2.45–235) 0.006
Modified by antidepressantsc
no antidepressants 89 1.88 (0.63–5.64) 0.257
Antidepressants 89 21.6 (2.75–170) 0.003
Modified by antidepressantsa
no antidepressants 76 2.95 (0.53–16.6) 0.218
Antidepressants 76 23.2 (2.95–182) 0.003
Notes: Modified analyses include interaction effects. aAdjusted for age, sex, and 
cognition (MMse). bAdjusted for age, sex, cognition (MMse), pain (MOBID-2), and 
depression (CsDD). cUnadjusted.
Abbreviations: CsDD, Cornell scale for Depression in Dementia; MMse, Mini-
Mental state examination; MOBID-2, Mobilization-Observation-Behavior-Intensity-
Dementia-2 Pain scale.
Figure 3 Cox proportional hazard plot: discontinuation risk stratified on treatment 
allocation and antidepressant use.
Abbreviation: n06A, Antidepressant.

















4 5 6 7
Placebo Buprenorphine
Figure 4 Daytime activity during the first week of study treatment.
Notes: Actigraphy recording of total activity from 09:00 to 21:00 hours daily. 
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mean activity counts during the week before treatment 
started as the baseline activity score. Patients who received 
active treatment had significantly reduced daytime activity 
on day 2 of treatment compared with placebo (mixed model; 
Total AC: −16,967, p=0.005). This corresponds to a 21.4% 
decrease in total daytime activity in those who received 
active treatment. Comparing the mean daytime activity in 
the first week of treatment with baseline activity, we found 
that active treatment was associated with a 12.9% decrease in 
mean Total AC, but this effect was not statistically significant 
(mixed model; p=0.053).
Discussion
To our knowledge, this is the first placebo-controlled study 
investigating the tolerability and observed adverse events of 
buprenorphine TDS in nursing home patients with moder-
ate to severe dementia. Patients who used antidepressants 
and received active treatment had the highest risk of dis-
continuation; this suggests a clinically relevant interaction 
between antidepressants and buprenorphine in people with 
dementia. Buprenorphine significantly reduced daytime 
activity as measured by actigraphy on the second day of 
treatment compared with placebo, supporting reports from 
nursing home staff of increased sedation/somnolence as 
the most frequent adverse effect. The poor tolerability of 
buprenorphine TDS due to the high risk of neurological and 
psychiatric adverse events should be considered carefully by 
clinicians before prescribing to people with dementia, and 
particularly to patients who are also using antidepressants, 
which may further reduce tolerability. This study does not 
assess the efficacy of buprenorphine TDS for treating dif-
ferent types of pain in dementia, which should be addressed 
in future research.
In the active treatment group, 57% had reported adverse 
events. A recent meta-analysis of six randomized controlled 
studies (five were placebo controlled) found that 82% of 
elderly patients ($65) had adverse events of buprenorphine 
TDS.27 The lower rate of reported adverse events in our 
study can most likely be attributed to our reliance on proxy 
observations of adverse events. Although self-report of symp-
toms is considered the gold standard, people with advanced 
dementia often have impaired ability to reliably report their 
symptom burden. For example, less than half of patients 
with MMSE #6 are able to comprehend any assessment 
scale used to self-report painful symptoms.28 In our study, 
mean MMSE was 7 at baseline; therefore, many could not 
self-report adverse effects of buprenorphine TDS. Mild 
adverse effects of buprenorphine are subjective, they may 
not be easily observable, and subtle changes such as reduced 
appetite, confusion, or agitation could be misinterpreted as 
neuropsychiatric symptoms in dementia which may not be 
attributed to study treatment by the proxy raters. Because 
people with communication difficulty due to advanced 
dementia cannot be expected to reliably self-report mild 
adverse events, the true prevalence of adverse events is likely 
to have been underestimated in our study due to observer bias. 
Therefore, this should be interpreted as a tolerability study 
presenting adverse events associated with discontinuation 
of treatment, rather than the absolute frequency of adverse 
events in people with dementia.
Although very frail patients with short life expectancy 
were not included in the trial, sudden clinical deterioration 
is difficult to predict and must be expected to occur during 
an extended follow-up period in nursing home patients with 
advanced dementia, regardless of exposure to a clinical 
intervention. The number of patients who were withdrawn 
from the study because of severe clinical deterioration with 
short life expectancy did not differ significantly between 
the active treatment and placebo groups, and our sample 
size and follow-up period were not designed to investigate 
whether buprenorphine use may be associated with increased 
mortality. Adverse events were registered on suspicion, based 
on detailed reports of clinical changes from nursing home 
staff. Even though we did not assess the likelihood of causality 
between the study treatment and each reported adverse event, 
we conclude that the difference in the total number of adverse 
events between active treatment and placebo can likely be 
attributed to adverse effects of buprenorphine.
Previous studies indicate that buprenorphine TDS is 
well tolerated in elderly patients, with studies reporting 
similar or lower rates of adverse events in healthy elderly 
patients compared with younger controls.29–31 In elderly 
patients without dementia, the most common adverse events 
associated with discontinuation of buprenorphine treatment 
are gastrointestinal – nausea (8.2%), vomiting (3.9%), and 
constipation (2.0%) – followed by neurological symptoms – 
dizziness (5.1%), somnolence (2.0%), and headache (2.0%).27 
In our study, psychiatric and neurological adverse effects 
were frequent, reported in 16 of patients who discontinued 
treatment (36.4%). Four patients (9.1%) who discontinued 
treatment had gastrointestinal symptoms. This indicates that 
psychiatric adverse events of buprenorphine may occur more 
frequently in people with dementia compared with cogni-
tively intact elderly patients. As buprenorphine has similar 
pharmacokinetic properties in elderly patients including those 
with renal impairment,29,32 this reduced tolerability is most 
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Buprenorphine TDS is absorbed slowly, and it reaches 
active concentration after ~24 hours and steady state during 
the first 72 hours in young healthy patients.35 Although phar-
macokinetics have not been investigated in the very old and 
frail, buprenorphine TDS appears to be absorbed at a similar 
rate in people aged $75 years compared to a younger con-
trol group.29 The largest drop in daytime activity observed 
in our study (recorded ~24–36 hours after administration) 
may therefore correspond to the first systemic exposure 
to buprenorphine. While the reduction in daytime activity 
during the first week of active treatment was not statistically 
significant, this was probably due to low sample size.
Depression is associated with the use of antidepressants 
in nursing home patients with dementia.17 Because depression 
was an inclusion criterion, we may have selected patients 
who used more antidepressants relative to other psycho-
tropic drugs. This may have enabled us to find a significant 
interaction between antidepressant use and buprenorphine 
discontinuation, while potential interactions between 
buprenorphine and other psychotropic drugs may have gone 
unnoticed. However, patients in the active treatment group 
generally used less psychotropic drugs compared with the 
placebo group and had a lower prevalence of antidepressant 
use (31.8%) than that expected from recent reports in people 
with dementia (~40%).36,37 Thus, the observed interaction 
between antidepressants and buprenorphine is likely to be 
of clinical relevance. While we did not find significant inter-
action effects between other psychotropic drugs and active 
buprenorphine, this may be due to insufficient power rather 
than the absence of such effects.
As shown in two recent studies, the use of opioid anal-
gesics in the oldest nursing home patients with dementia is 
increasing.7,9 Age is associated with increased pain, frailty, 
and dementia. In patients with severe pain, or very frail 
patients, it may be difficult to achieve full analgesic effect 
as the type or dose of analgesics required may not be toler-
ated by the patient. Because patients with dementia have not 
been included in safety studies, the evidence base to ensure 
appropriate prescribing is lacking. In the DEP.PAIN.DEM 
trial, neither did we find a significant change in pain intensity 
in either of the buprenorphine or placebo TDS groups dur-
ing follow-up, nor did we find a significant treatment effect 
on pain between these groups.39 However, this may be due 
to insufficient sample size as the DEP.PAIN.DEM trial was 
not powered to assess the effect of buprenorphine on pain. 
Further studies should investigate the efficacy and tolerability 
of buprenorphine and other opioid analgesics for pain in 
nursing home patients with dementia and painful symptoms. 
Use of opioids in people with dementia should be based on a 
careful risk–benefit evaluation, including regular assessments 
of pain and potential adverse effects, in combination with 
nonpharmacological strategies as appropriate.34
This study has limitations. The included patients had clini-
cally significant depressive symptoms at baseline, but not all 
had pain. Therefore, our results may not be generalizable to 
patients who receive buprenorphine for pain. Prescribers may 
have had a lower threshold for discontinuation upon adverse 
events in this study, for instance, the risk–benefit consider-
ation may have been shifted toward a greater awareness of 
adverse events as the treatment was prescribed off-label. 
The patients’ level of vulnerability to adverse events, and 
the relative prevalence of different types of adverse events, 
may also be different in people with advanced dementia 
and severe pain as opposed to the current sample which 
consisted of people with advanced dementia and depres-
sion without severe pain. Similarly, the adverse effects of 
buprenorphine TDS may differ between subgroups of pain 
patients (neuropathic/nociceptive; acute/chronic pain). Since 
the focus of the DEP.PAIN.DEM trial was to investigate the 
efficacy of pain treatment on depression, we did not diag-
nose the type and duration of pain. Therefore, future studies 
should investigate the safety and efficacy of buprenorphine 
TDS in people with dementia and different types of pain. 
Patients who were prescribed buprenorphine rather than acet-
aminophen used more regular analgesics and/or had difficulty 
swallowing tablets. This means that we may have selected 
more frail/multimorbid patients to receive buprenorphine/
placebo as opposed to acetaminophen/placebo in the DEP.
PAIN.DEM trial. However, this prescribing strategy mirrors 
clinical practice with a stepwise increase from non-opioid 
to opioid analgesics and the choice of transdermal formu-
lation for patients who cannot swallow tablets; therefore, 
our sample should be similar to nursing home patients with 
dementia who receive buprenorphine TDS. We included a 
mixture of opioid-naïve patients, patients who had previously 
discontinued or received sporadic as-needed treatment with 
an opioid, and patients who received ongoing buprenorphine 
treatment; this is likely to have affected the observed pattern 
of adverse events which is not representative of an opioid-
naïve population. Despite randomization, we found that 
patients who received active treatment used significantly 
less psychotropic and anticholinergic drugs, and fewer used 
antidepressants. This could potentially influence the results, 
as these drugs are associated with adverse outcomes in 
people with dementia.38 However, because these drugs were 
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adverse events in the active treatment group is likely caused 
by buprenorphine. We have not controlled for changes in 
concomitant drug use during study treatment. Physicians 
were instructed to avoid changes, particularly to psychotropic 
and analgesic drugs, but drug changes were not assessed in 
the 17 patients who discontinued treatment before week 6 
assessment. The DEP.PAIN.DEM trial was designed with 
90% power to detect a 2-point difference in depression 
(CSDD) from baseline to 13-week follow-up between active 
treatment (acetaminophen or buprenorphine) and placebo.39 
For the secondary outcomes reported in the present study, 
no a priori power analyses have been conducted. This is an 
important limitation, and the findings from the current analy-
ses should therefore be interpreted with caution, in particular 
for the subgroup analyses with lower sample sizes. Because 
the estimated effect sizes have very wide CIs, the exact 
magnitude of increased risk remains uncertain. However, 
we have identified significant between-group differences in 
reported adverse events and discontinuation risk. Although 
adverse events were assessed by proxy, and are therefore 
likely to be affected by observer bias, the placebo-controlled 
design provides strong evidence that the difference in adverse 
events is caused by the active drug rather than observer bias. 
Therefore, we find it important to share the presented results. 
Further studies are needed to provide evidence of the safety 
and efficacy of transdermal buprenorphine for different types 
of pain in people with dementia.
Conclusion
Buprenorphine appears to be poorly tolerated in people with 
dementia, with a higher prevalence of psychiatric adverse 
events compared with previous studies in cognitively 
intact elderly patients. Initiation of buprenorphine therapy 
is associated with reduced daytime activity. Although no 
dose adjustment is recommended for buprenorphine in 
elderly patients, our data suggest that people with dementia 
are susceptible to adverse events even at the lowest initial 
dose. When buprenorphine is administered to people with 
dementia, the patients’ general condition pre- and posttreat-
ment should therefore be monitored carefully, including 
assessments of intended and adverse treatment effects, 
particularly in patients using antidepressants.
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